← All trials
NCT07200908
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 27, 2025
- Primary completion
- Jun 30, 2027
- Completion date
- Sep 30, 2029
- First posted
- Oct 1, 2025
- Last posted
- Nov 17, 2025
- Enrollment
- 172
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Bluejay Therapeutics, Inc.Lead sponsor
- Bluejay Therapeutics, Inc.Official
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.